Methscopolamine bromide

The answer is c. (Hardman, pp 156-158.) A wide variety of clinical conditions are treated with antimuscarinic drugs. Dicyclomine hydrochloride and methscopolamine bromide are used to reduce Gl motility, although side effects—dryness of the mouth, loss of visual accommodation, and difficulty in urination—may limit their acceptance by patients. Cyclopentolate hydrochloride is used in ophthalmology for its mydriatic and cycloplegic properties during refraction of the eye. Trihexyphenidyl hydrochloride is one of the important antimuscarinic compounds used in the treatment of parkinsonism. For bronchodilation in patients with bronchial asthma and other bronchospastic diseases, ipratropium bromide is used by inhalation. Systemic adverse reactions are low because the actions are largely confined to the mouth and airways. 

Children (older than 1 year of age) 12.5 to 50 mg 4 times daily. METHSCOPOLAMINE BROMIDE 2.5 mg 30 minutes before meals and 2.5 to 5 mg at bedtime. 

Butylscopolamine and methscopolamine bromide, quaternary ammonium derivatives of scopolamine without its central actions and homatropine methylbromide, a quaternary derivative of homatropine, are less potent than atropine in antimus-carinic activity. They are used for their antispasmodic action in gastroenterology. The usual oral doses act for 6-8 hours. However, the quaternary ammonium derivatives are poorly absorbed after an oral dose and their eficacy is therefore very variable. Only parenteral administrations are recommended. 

The derivatives of scopolamine (7) prepared by similar methods are available commercially. These include methscopolamine bromide (12), methscopolamine nitrate, and genoscopolamine (scopolamine N-oxide, 13). 

---